fashion -WSS

fashion

author：focus 2025-08-12 06:43:00 - browse：878

In the center, three researchers examine a DNA helix. Two people stand in the front, one puts an apple into a capsule containing vegetables, the other holds a check list while standing next to a pile of medicines. On the right side, a scientist injects into mitochondria while another takes notes. A person behind the duo looks at a projection of a brain. On the left side, a client looks at a heart projection from a device held by a robot — biotech coverage from STAT — Adobe

When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis.

But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca.

The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STAT Breakthrough Summit in San Francisco.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Excited delirium, Elijah McClain, and emergency physicians

entertainment

hotspot

knowledge

WSS

Diversify hospital leadership teams to protect BIPOC patient health

Abortion pill case raises question: who can sue the FDA?

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Roche subsidiary Foundation Medicine opens new headquarters

Abortion pill Supreme Court ruling could impact entire drug industry

Patient advocates debate FDA's accelerated approval process

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

There's no autism epidemic. It's an autism diagnosis epidemic

Heart attack and stroke risk calculators need revising

Scientists boost immune system in aging mice by making it youthful

Supreme Court strikes down use of affirmative action

Supreme Court mifepristone arguments center on docs' right to sue

After affirmative action ruling, medical educators look to 'holistic review'

Patient advocates debate FDA's accelerated approval process

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Senate panel clears PBM, hopsital reforms

hotspot

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Ambulance rides for just $100? Advisers want major billing fixes

There's no autism epidemic. It's an autism diagnosis epidemic

Abortion clinic in Cancun will cater to Americans

Study says nonprofit hospitals fall short in charity care spending

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

entertainment

hotspot

knowledge

entertainment